Faron Set To Fly As Bexmarilimab Shows Promise

IO Candidate Offers Unique Mode Of Action

 
• By Kevin Grogan

Data have shown that the Finnish firm's bexmarilimab has the potential to be the first macrophage immune checkpoint therapy and big pharma are getting interested in a licensing deal.

Jalkanen_Markku
Markku Jalkanen • Source: Faron

After a couple of years in the doldrums, Faron Pharmaceuticals Oy's star is rising again on the prospects of its next-generation immunotherapy bexmarilimab becoming a blockbuster.

The Finland-headquartered company has given a business update on progress made in 2022 when, according to CEO Markku Jalkanen, Faron...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D